Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC

Grand Rounds: Improving quality of patient-centred care

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer

A combined PET-MRI scan could improve treatment for patients with early breast cancer

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer

Comment: EBCC 2024 highlights

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status